Sintilimab injection is a monoclonal antibody against human IgG4, which can specifically bind to PD-1 molecule on the surface of T cells, thus blocking PD-1/PD-L1 pathway leading to tumor immune tolerance, starting T cells to kill tumor cells, so as to achieve the purpose of anti-tumor. Here, PDCD1 is linked to neoplasm.